Oncology

Ivonescimab plus chemotherapy improved survival compared with current standard treatment durvalumab plus chemotherapy in advanced biliary tract cancer.

Adding darolutamide to hormone therapy and radiotherapy improved metastasis-free survival in high-risk prostate cancer, according to research presented at ESMO 2026.

Osimertinib plus savolitinib cut death risk by 32% versus chemotherapy in selected patients with resistant lung cancer, according to new trial results presented at ESMO 2026.

Intismeran improved melanoma outcomes and reduced reoccurrence by over 40%, but leaked trial data fell short of investor expectations, hitting Moderna and Merck shares.

I went into cancer care and cancer research because, when I was a fellow, it was the medical specialty with the largest number of challenges…

Early clinical results reveal that the novel KRAS G12D inhibitor GFH375 achieves a 41% response rate and 97% disease control in advanced…

The DESTINY-Breast11 phase 3 trial presented at ESMO 2025 revealed that the anthracycline-free neoadjuvant T-DXd-THP regimen achieved a 67.3% pathologic complete response rate.

This year’s European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress took place in the vibrant and historic city of…